Sekine, Hiroshi
Kijima, Yoshikazu
Kobayashi, Masao
Itami, Jun
Takahashi, Kana
Igaki, Hiroshi
Nakai, Yasuo
Mizutani, Hitoshi
Nomoto, Yoshihito
Kikuchi, Katsuko
Matsushita, Haruo
Nozawa, Keiko
Funding for this research was provided by:
The Japan Agency for Medical Research and Development (16ck0106061h0003)
Article History
Received: 23 August 2019
Accepted: 20 March 2020
First Online: 3 May 2020
Compliance with ethical standards
:
: Hiroshi Sekine received a research grant from the Japan Agency for Medical Research and Development for this study. Yoshikazu Kijima has no conflicts of interest. Masao Kobayashi has no conflicts of interest. Jun Itami received personal fees from HekaBio, ItoChu, and Kay-J, which were unrelated to the submitted work. Kana Takahashi has no conflicts of interest. Hiroshi Igaki received a research grant from HekaBio and personal fees from ItoChu, which were unrelated to the submitted work. Yasuo Nakai received personal fees from ONO Pharmaceutical Co. LTD, Novartis Pharma K.K, and Jiho, Inc., which were unrelated to the submitted work. Hitoshi Mizutani received a grant from the Japan Agency for Medical Research and Development during the conduct of the study; currently serves as a consultant to Asahikasei Pharma Co. Ltd., Kao Corp., Celgene Co. Ltd., Tanabe Mitsubishi Co. Ltd., Kinoushokuhin Kenkyusho, Sato Pharma, Eli Lilly Japan K.K., Maruishi Pharma Co. Ltd., Leo Pharma, Kaken Pharma, and FUJIFILM Toyama Chemical Co., Ltd.; received lecture and consultant fees from Maruho Co. Ltd.; received lecture and transportation fees from Jansen Pharma; received consultancy and manuscript fees from Shionogi Pharma Co. Ltd., and Bayer Pharma.; and received lecture fees from Taiho Pharma, Grafa Laboratory, Kyorin Pharma, Inforward Co. Ltd., Astellas Pharma., Kaken Pharma., Novartis Pharma, Kyowa-Kirin Co. Ltd., Eisai Co. Ltd., Torii Co. Ltd., Absolute Co. Ltd., Tsumura Co. Ltd., Nippon Shinyaku Co. Ltd., POLA-Pharma, and Ushio Electric Co. Ltd., which were unrelated to the submitted work. Yoshihito Nomoto has no conflicts of interest. Katsuko Kikuchi received a grant and personal fees from POLA-Pharma and personal fees from Maruho Co. Ltd. and TOKIWA Pharmaceutical Co. Ltd., which were unrelated to the submitted work. Haruo Matsushita has no conflicts of interest. Keiko Nozawa has no conflicts of interest.
: This study was approved by the Institutional Review Board of each institute and conducted according to the 1964 Declaration of Helsinki and its later amendments, as well as the Ethical Guidelines for Medical Health Research Involving Human Subjects (2014) by the Japanese Ministry of Health and Welfare and the Ministry of Education, Culture, and Technology.
: Informed consent was obtained from all participants included in the study.